cjc-1295 ipamorelin peptide therapy clinic + CJC-1295 + Ipamorelin — Peptide

mL insulin syringe (U-50) Holds 0.5 mL

Headaches Headaches are among the more commonly reported systemic side effects with peptide therapies and hormone-related treatments

This consideration affects protocol design and subject selection in research settings

Protocols need to be adhered to and monitored closely

**Medical supervision** - Peptide therapy should only be used under the care of a licensed provider 2

13-residue N-terminal extension (MFPAMPLSSFVNQ) for extended stability Formula / M.W.: C 400 H 625 N 111 O 115 S 9 , ~9111 g/mol CAS: 946870-92-4 Disclaimer This product is intended for laboratory research use only